吸入激素治疗能否改变幼儿新发哮喘的自然病程?
本文讨论对具有持续哮喘风险的喘息幼儿(定义为喘息且存在气流受限或气道高反应性,或两者兼有)使用吸入皮质激素(ICS)以改变疾病自然病程的潜在作用。文章指出,尽管早期使用ICS改变哮喘自然病程的期望普遍存在,但其作用尚未明确,并提出了更个性化的治疗思路,即每日或间歇ICS治疗可能使部分儿童获益,同时概述了其他可能用于疾病修饰的新兴疗法。
要点
- 早期喘息常见,但持续哮喘较少;进展为持续哮喘的儿童早期即可见肺功能异常和气道重塑。
- 早期使用ICS能否改变哮喘自然病程尚不明确,需个体化评估每日或间歇治疗策略。
- 对具有持续哮喘风险的喘息幼儿,可考虑ICS治疗以潜在修饰疾病进程。
核心结论
- 早期使用ICS改变哮喘自然病程的作用尚未明确,需更个性化治疗。
- 每日或间歇ICS治疗可能使部分具有持续哮喘风险的喘息幼儿获益。
研究设计与样本
- 本文为综述,讨论ICS治疗对具有持续哮喘风险的喘息幼儿自然病程的潜在影响。
主要发现
- 进展为持续哮喘的儿童早期即可见肺功能异常和气道重塑,且随时间加重。
- 早期使用ICS改变哮喘自然病程的期望普遍存在,但作用未明确。
- 提出了更个性化治疗思路,部分儿童可能从每日或间歇ICS治疗中获益。
关键数值与推荐
- 持续哮喘风险定义为喘息且存在气流受限或气道高反应性,或两者兼有。
临床怎么用
- 对具有持续哮喘风险的喘息幼儿,可考虑个体化ICS治疗(每日或间歇)以潜在修饰疾病进程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although early childhood wheeze is common, persistent asthma is less common. However, of those children who do progress to persistent asthma, lung function abnormalities and airway remodelling can already be seen early in life and can increase in magnitude with time. There has been a general expectation that early use of inhaled corticosteroid (ICS) could change the natural history of asthma if started in the young child with wheeze. Despite this expectation, the role of ICS therapy in altering the natural course of disease in children with emerging asthma is not well defined. Here we discuss the potential use of ICS therapy to alter the natural disease course in children at risk of persistent asthma (defined as wheeze and presence of airflow limitation or airway hyper-reactivity, or both). We present new information suggesting a more personalised treatment approach in which children might benefit from daily or intermittent ICS therapy. We also provide an overview of other emerging therapies that might be useful in disease modification for the wheezing young child at risk of persistent asthma.
引用
- Abrams EM, Szefler SJ, Becker AB, et al. Does inhaled steroid therapy help emerging asthma in early childhood? Lancet Respir Med. 2017. PMID: 28780183. doi:10.1016/S2213-2600(17)30295-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。